Residual effects of flurazepam and brotizolam on psychomotor performance.

Abstract:

:Residual effects of brotizolam (0.25 mg) and flurazepam (30 mg) were studied in healthy young adults. Performance and subjective assessments were observed from 7 to 8 h after overnight ingestion, and effects were compared with that of placebo. Visuo-motor coordination, visuo-mental processing time, visuo-motor reaction time and reading errors were not impaired with brotizolam. There were residual effects with 30 mg flurazepam. Visuo-motor coordination, visuo-mental processing time, visuo-motor reaction time, and reading errors were impaired compared with placebo and 0.25 mg brotizolam. Subjective assessments of performance correlated with measured performance. There was a decrease with flurazepam (visuo-motor coordination and visuo-mental processing time) compared with placebo.

journal_name

Br J Clin Pharmacol

authors

Krueger H,Müller-Limmroth W

doi

10.1111/j.1365-2125.1983.tb02309.x

subject

Has Abstract

pub_date

1983-01-01 00:00:00

pages

347S-351S

eissn

0306-5251

issn

1365-2125

journal_volume

16 Suppl 2

pub_type

临床试验,杂志文章
  • Safeguarding the process of drug administration with an emphasis on electronic support tools.

    abstract:AIMS:The aim of this work is to understand the process of drug administration and identify points in the workflow that resulted in interventions by clinical information systems in order to improve patient safety. METHODS:To identify a generic way to structure the drug administration process we performed peer-group dis...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/bcp.12191

    authors: Seidling HM,Lampert A,Lohmann K,Schiele JT,Send AJ,Witticke D,Haefeli WE

    更新日期:2013-09-01 00:00:00

  • Multicompartment compliance aids in the community: the prevalence of potentially inappropriate medications.

    abstract:AIMS:To assess the prevalence of potentially inappropriate medications (PIMs) use in a population of community-based multicompartment compliance aid (MCA) users in north-east Scotland. METHODS:Data for MCAs dispensed by 48 of the 50 community pharmacies in Aberdeen City between 1st June to 31st October 2014, together ...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/bcp.13220

    authors: Counter D,Stewart D,MacLeod J,McLay JS

    更新日期:2017-07-01 00:00:00

  • Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects.

    abstract::1. The effects of a single oral dose of enalapril 10 mg on serum ACE activity and blood pressure in relation to the ACE genotype were studied in 27 healthy men, n = 9 each of genotype DD, ID and II, in a parallel group study design. 2. Before treatment serum ACE activity differed significantly between the genotypes, w...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2125.1995.tb04419.x

    authors: Todd GP,Chadwick IG,Higgins KS,Yeo WW,Jackson PR,Ramsay LE

    更新日期:1995-02-01 00:00:00

  • Blood pressure response to labetalol in twice and three times daily administration during a 24-hour period.

    abstract::1 The anti-hypertensive effect of labetalol given twice or three times daily was evaluated in ambulant subjects with essential hypertension by recording blood pressure directly for 24 h before and after 15 d of labetalol administration (daily dose 600-1800 mg). 2 Labetalol reduced 24 h systolic and diastolic blood pre...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2125.1982.tb01886.x

    authors: Mancia G,Pomidossi G,Parati G,Bertinieri G,Grassi G,Navone F,Ferrari A,Gregorini L,Zanchetti A

    更新日期:1982-06-01 00:00:00

  • Proof of pharmacology of Org 48775-0, a p38 MAP kinase inhibitor, in healthy volunteers.

    abstract:AIM:To investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of the highly selective oral p38alpha/beta mitogen-activated protein (MAP) kinase inhibitor Org 48,775-0 in a first-in-human study. METHODS:In the single ascending dosing (SAD) study, an oral dose of Org 48,775-0 (0.3-600 mg) was evalua...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/bcp.14655

    authors: Moerland M,Kales AJ,Broekhuizen K,Nässander U,Nelissen R,de Kam ML,Peeters PAM,Burggraaf J

    更新日期:2020-11-17 00:00:00

  • Suppression of human monocyte tumour necrosis factor-alpha release by glucocorticoid therapy: relationship to systemic monocytopaenia and cortisol suppression.

    abstract:AIMS:Glucocorticoids suppress the release of tumour necrosis factor-alpha (TNF-alpha) by macrophages in vitro and cause monocytopaenia in vivo. These actions may contribute to anti-inflammatory and immunosuppressant effects. We therefore examined relationships between prednisolone concentration, suppression of monocyte...

    journal_title:British journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2125.1997.00586.x

    authors: Steer JH,Vuong Q,Joyce DA

    更新日期:1997-04-01 00:00:00

  • The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.

    abstract:AIMS:Angiotensin receptor blockers (ARBs) are renoprotective and targeted to blood pressure. However, ARBs have multiple other (off-target) effects which may affect renal outcome. It is unknown whether on-target and off-target effects are congruent within individuals. If not, this variation in short term effects may ha...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/bcp.12655

    authors: Schievink B,de Zeeuw D,Parving HH,Rossing P,Lambers Heerspink HJ

    更新日期:2015-10-01 00:00:00

  • Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy.

    abstract::1. The new intravenous bisphosphonate drug aminohydroxypropylidine bisphosphonate (APD) is effective in treating the hypercalcaemia of malignant disease, but the optimum dose regimen is not yet established. We have treated twenty-seven patients with malignant hypercalcaemia (corrected calcium greater than 3.00 mmol l-...

    journal_title:British journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2125.1989.tb05426.x

    authors: Davis JR,Heath DA

    更新日期:1989-09-01 00:00:00

  • Effects of locally administered anticholinesterase agents on the secretory response of human eccrine sweat glands to acetylcholine and carbachol.

    abstract::The effects of locally administered physostigmine and di-isopropylphosphorofluoridate (DFP) were compared on the secretory response of sweat glands to intradermally injected acetylcholine and carbachol in healthy male volunteers (physostigmine: six subjects; DFP: one subject). The response to acetylcholine reached its...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2125.1986.tb05166.x

    authors: Longmore J,Jani B,Bradshaw CM,Szabadi E

    更新日期:1986-02-01 00:00:00

  • The first-in-human study of CNTO 7160, an anti-interleukin-33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis.

    abstract:AIMS:To assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of CNTO 7160, an anti-interleukin-33 receptor (IL-33R) monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis (AD). METHODS:In Part 1 of this Phase I, randomized, double-blind, placebo-c...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/bcp.14361

    authors: Nnane I,Frederick B,Yao Z,Raible D,Shu C,Badorrek P,van den Boer M,Branigan P,Duffy K,Baribaud F,Fink D,Yang TY,Xu Z

    更新日期:2020-12-01 00:00:00

  • The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.

    abstract:WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT:* The variability in drug metabolism has been recognized as an important factor in the occurrence of adverse effects or lack of therapeutic efficacy. * The metabolism of the third-generation beta(1)-receptor antagonist nebivolol has been shown to be highly dependent on cytochrom...

    journal_title:British journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2125.2006.02796.x

    authors: Lefebvre J,Poirier L,Poirier P,Turgeon J,Lacourciere Y

    更新日期:2007-05-01 00:00:00

  • A comparison of the pharmacokinetics of nisoldipine in elderly and young subjects.

    abstract::Nine young and 12 elderly healthy volunteers received nisoldipine 10 mg once a day for 7 days. Plasma nisoldipine concentrations were measured on Day 1 and on Day 7. Higher plasma drug concentrations were observed in the elderly group than in the young group with the values for AUC being approximately doubled in the e...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2125.1991.tb05547.x

    authors: Baksi AK,Edwards JS,Ahr G

    更新日期:1991-03-01 00:00:00

  • A comparative study of atenolol and metoprolol in the treatment of hypertension.

    abstract::1 In an open, randomized cross-over investigation of thirteen patients (nine and four women, aged 37-67 years) with mild or moderate essential hypertension a comparison between atenolol and metoprolol was carried out in order to study the effects of 50, 100 and 200 mg given once daily on blood pressure and heart rate ...

    journal_title:British journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2125.1981.tb01326.x

    authors: Rasmussen S,Arnung K,Eskildsen PC,Nielsen PE

    更新日期:1981-12-01 00:00:00

  • Effects of dilevalol (R,R-labetalol) compared with nifedipine on heart rate, blood pressure and muscle blood flow at rest and on exercise in hypertensive patients.

    abstract::1. Dilevalol (R,R-labetalol) is a non-selective beta-adrenoceptor antagonist with beta 2-adrenoceptor agonist activity. Its effects after 1 month's administration on heart rate, blood pressure and muscle blood flow were studied in a double-blind crossover comparison with nifedipine in 16 hypertensive patients. 2. Dile...

    journal_title:British journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2125.1993.tb04192.x

    authors: Walley T,Tsao Y,Scott A,Mackay E,Vandenburg M,Breckenridge A

    更新日期:1993-06-01 00:00:00

  • Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans.

    abstract:AIMS:To investigate the effect of multiple dosing with montelukast, a selective leukotriene-receptor antagonist, on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans. METHODS:A two-period, randomized crossover study was conducted in 10 healthy subjects. After administration of oral doses of placebo ...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2125.2006.02764.x

    authors: Kim KA,Park PW,Kim KR,Park JY

    更新日期:2007-03-01 00:00:00

  • Mercaptopurine in childhood leukaemia: the effects of dose escalation on thioguanine nucleotide metabolites.

    abstract::The current U.K. trial protocol (UKALL XI) for childhood lymphoblastic leukaemia demands mercaptopurine (MP) dose escalation in children who tolerate daily 75 mg/m2 MP (100% dose) without cytopenias. The previous trial (UKALL X) did not. MP metabolism was studied in a group of UKALL XI children (n = 21) who tolerated ...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1046/j.1365-2125.1996.44921.x

    authors: Lennard L,Welch J,Lilleyman JS

    更新日期:1996-10-01 00:00:00

  • Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors.

    abstract:WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT:• Clinical cases reported that fatal acute liver failure occurred when paracetamol (acetaminophen) was co-administrated with some tyrosine kinase inhibitors (TKIs). The direct inhibition of UDP-glucuronosyltransferase activities has been identified as a mechanism of potentiation...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2125.2011.03911.x

    authors: Liu Y,Ramírez J,Ratain MJ

    更新日期:2011-06-01 00:00:00

  • Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2.

    abstract::1. Studies using human liver microsomes and six recombinant human CYP isoforms (i.e. CYP1A2, 2A6, 2B6, 2D6, 2E1 and 3A4) were performed to identify the cytochrome P450 (CYP) isoform(s) involved in the ring 4-hydroxylation and side-chain N-desisopropylation of propranolol enantiomers in humans. 2. alpha-Naphthoflavone ...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2125.1995.tb04472.x

    authors: Yoshimoto K,Echizen H,Chiba K,Tani M,Ishizaki T

    更新日期:1995-04-01 00:00:00

  • Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers.

    abstract::Twelve healthy volunteers were given orally placebo, itraconazole 100 mg or terbinafine 250 mg for 4 days. Midazolam 7.5 mg was ingested on the fourth day, after which plasma samples were collected and psychomotor performance tests carried out for 17 h. Itraconazole increased the area under the midazolam concentration...

    journal_title:British journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Ahonen J,Olkkola KT,Neuvonen PJ

    更新日期:1995-09-01 00:00:00

  • Stereoselectivity in the urinary excretion of the mercapturates of (R-) and (S-) alpha-bromoisovalerylurea in man.

    abstract::1. alpha-Bromoisovalerylurea (BIU) is a racemic drug that is metabolized by glutathione conjugation. The urinary excretion of the separate diastereomeric mercapturates formed from (S)- and (R)-BIU in healthy young human volunteers was investigated. 2. A pronounced stereoselectivity was observed: the mercapturate forme...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2125.1989.tb05407.x

    authors: te Koppele JM,Schipper C,Breimer DD,Mulder GJ

    更新日期:1989-08-01 00:00:00

  • Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism.

    abstract:AIMS:To obtain in vivo evidence for the involvement of cytochrome P450 (CYP) 3A4 in the metabolism of brotizolam. METHODS:Fourteen healthy male volunteers received erythromycin 1200 mg day(-1) or placebo for 7 days in a double-blind randomized crossover manner. On the 6th day they received a single oral 0.5-mg dose of...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2125.2005.02380.x

    authors: Tokairin T,Fukasawa T,Yasui-Furukori N,Aoshima T,Suzuki A,Inoue Y,Tateishi T,Otani K

    更新日期:2005-08-01 00:00:00

  • Efficacy, safety and pharmacokinetics of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control.

    abstract:AIMS:The objectives were to investigate the pharmacokinetics, pharmacodynamics and safety of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control, and then recommend the dosage regimen for Phase 2b/3 studies. METHODS:Three clinical studies were performed. First, 16 healthy subject...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/bcp.14076

    authors: Wang H,Shao F,Liu X,Xu W,Ou N,Qin X,Liu F,Hou X,Hu H,Jiang J

    更新日期:2019-11-01 00:00:00

  • Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with the hf-capsule.

    abstract::1. The absorption of ciprofloxacin from different regions of the human gastrointestinal tract was investigated in four healthy males using a remote-controlled drug delivery device (hf-capsule). 2. Significant differences in AUC were observed in the control study (oral administration of ciprofloxacin solution without t...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2125.1990.tb03740.x

    authors: Harder S,Fuhr U,Beermann D,Staib AH

    更新日期:1990-07-01 00:00:00

  • Chemical design of cilazapril.

    abstract::1. The three dimensional requirements for inhibition of ACE (angiotensin converting enzyme) were investigated in order to facilitate design of a more potent and selective antihypertensive agent. 2. All compounds designed possessed a bicyclic unit incorporating carboxylate and amidic carbonyl groups together with a thi...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2125.1989.tb03474.x

    authors: Attwood MR

    更新日期:1989-01-01 00:00:00

  • N-acetylcysteine fails to attenuate haemodynamic tolerance to glyceryl trinitrate in healthy volunteers.

    abstract::1. The effects of chronic dosing with N-acetylcysteine (NAC), on nitrate-induced haemodynamic changes during the acute and chronic treatment of healthy volunteers with glyceryl trinitrate (GTN) patches (Transiderm nitro) has been investigated. 2. Seven volunteers were treated in a double-blind randomised crossover man...

    journal_title:British journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2125.1989.tb03522.x

    authors: Hogan JC,Lewis MJ,Henderson AH

    更新日期:1989-10-01 00:00:00

  • Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin.

    abstract:AIM:Canagliflozin is an SGLT2 inhibitor approved for the treatment of type-2 diabetes. A dynamic population pharmacokinetic-pharmacodynamic (PK/PD) model relating 24-h canagliflozin exposure profiles to effects on glycosylated haemoglobin was developed to compare the efficacy of once-daily and twice-daily dosing. METH...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/bcp.13180

    authors: de Winter W,Dunne A,de Trixhe XW,Devineni D,Hsu CH,Pinheiro J,Polidori D

    更新日期:2017-05-01 00:00:00

  • TPMT*26 (208F-->L), a novel mutation detected in a Chinese.

    abstract:AIMS:Azathioprine, mercaptopurine and thioguanine are commonly used to treat autoimmune disorders, leukaemia and solid organ transplantation. However, azathiopurine and its metabolites can also cause adverse reactions such as myelosuppression. These manifestations may be attributed to polymorphisms or mutations in the ...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/j.1365-2125.2009.03405.x

    authors: Kham SK,Soh CK,Aw DC,Yeoh AE

    更新日期:2009-07-01 00:00:00

  • Undertreatment of hypertension and hypercholesterolaemia in children and adolescents with type 1 diabetes: long-term follow-up on time trends in the occurrence of cardiovascular disease, risk factors and medications use.

    abstract:AIMS:The aims of the present study were, firstly, to evaluate long-term trends in the occurrence and treatment of cardiovascular disease (CVD) risk factors and the occurrence of CVD events in children with type 1 diabetes mellitus (T1DM) and, secondly, to assess the determinants of undertreatment of CVD risk factors. ...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/bcp.13482

    authors: Ahmadizar F,Souverein P,de Boer A,Maitland-van der Zee AH

    更新日期:2018-04-01 00:00:00

  • Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome.

    abstract:AIMS:To develop a population pharmacokinetic model for mycophenolic acid (MPA) in children with idiopathic nephrotic syndrome (INS) treated with mycophenolate mofetil (MMF), identify covariates that explain variability and determine the Bayesian estimator of the area under the concentration-time curve over 12 h (AUC(0-...

    journal_title:British journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1111/j.1365-2125.2010.03615.x

    authors: Zhao W,Elie V,Baudouin V,Bensman A,André JL,Brochard K,Broux F,Cailliez M,Loirat C,Jacqz-Aigrain E

    更新日期:2010-04-01 00:00:00

  • First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G-protein-biased sphingosine-1 phosphate receptor-1 agonist for endothelial protection.

    abstract:AIMS:SAR247799 is a selective G-protein-biased sphingosine-1 phosphate receptor-1 (S1P1 ) agonist with potential to restore endothelial function in vascular pathologies. SAR247799, a first-in-class molecule differentiated from previous S1P1 -desensitizing molecules developed for multiple sclerosis, can activate S1P1 wi...

    journal_title:British journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1111/bcp.14422

    authors: Bergougnan L,Armani S,Golor G,Tardat A,Vitse O,Hurbin F,Scemama M,Poitiers F,Radzik D,Gaudin C,Hovsepian L,Muslin AJ,Kirkesseli S,Deutsch P,Parkar AA

    更新日期:2020-06-10 00:00:00